



Vaccine Equity and Immunization Program Evaluation

Guest Editors:

Dr. Mounia Hocine

Conservatoire National des Arts
et Metiersdisabled, Paris, France

Dr. Mahmoud Zureik

EPI-PHARE Scientific Interest
Group in Epidemiology of Health
Products from the French
National Agency for the Safety of
Medicines and Health Products
and the French National Health
Insurance, 93285 Saint-Denis,
Cedex, France

Deadline for manuscript
submissions:

31 August 2024

Message from the Guest Editors

Dear Colleagues,

Establishing a new vaccination program requires a commitment to equity. It is crucial to develop strategies that reach high-priority groups, such as healthcare workers or highly susceptible members of the population like older or immunocompromised individuals. It is equally important to ensure that vaccination is available to all sections of the community, including socio-economic and minority groups that have proven harder to reach in the past. Achieving this may require new engagement strategies, such as tailored community engagement plans, to communicate the vaccination's benefits and risks effectively. Both domestic and international funding should be coordinated and delivered to support these efforts. Finally, evaluating the vaccination program is imperative to demonstrate its value, ensure accountability, and learn lessons for the future.

This Special Issue welcomes scholars who are working on developing, implementing, or evaluating new immunization programs, with a focus on vaccine equity, to submit their work. The deadline for submissions is August 2024.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com